NasdaqGS:IDYABiotechs
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus
IDEAYA Biosciences (IDYA) enrolled the first patient in its Phase 1 IDE892 trial for MTAP-deleted solid tumors and updated investors on its broader MTAP-deletion and CDKN2A-deficiency pipeline. The company also trimmed certain combination studies.
See our latest analysis for IDEAYA Biosciences.
The latest IDE892 trial update comes after a 1-month share price return of 9.32% and a 1-year total shareholder return of 78.09%, suggesting recent momentum on top of already strong longer term...